Publications by authors named "Michael Wolden"

Claim this Profile
A
A time trade-off study in the UK, Canada and the US to estimate utilities associated with the treatment of haemophilia.
Anna Okkels, Cecilie Yssing, Michael Lyng Wolden, Mohd Nawi Wahid

Health Qual Life Outcomes· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular events, mortality, early retirement and costs in >50 000 persons with chronic heart failure in Sweden.
Katarina Steen Carlsson, Mads Faurby, Kristoffer Nilsson, Michael Lyng Wolden

ESC Heart Fail· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic burden of atherosclerotic cardiovascular disease: a matched case-control study in more than 450,000 Swedish individuals.
Katarina Steen Carlsson, Kristoffer Nilsson, Michael Lyng Wolden, Mads Faurby

BMC Cardiovasc Disord· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atherosclerotic Cardiovascular Disease in Type 2 Diabetes: A Retrospective, Observational Study of Economic and Clinical Burden in Sweden.
Katarina Steen Carlsson, Mads Faurby, Kristoffer Nilsson, Michael Lyng Wolden

Diabetes Ther· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nationwide cardiovascular risk categorization: applying the European Society of Cardiology guidelines to the Swedish National Diabetes Register.
Björn Eliasson, Jan Ekelund, Cecilia Nagorny Holmberg, Michael Lyng Wolden, Kasper Sommer Matthiessen

Eur J Prev Cardiol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study.
Vanita R Aroda, Mads Faurby, Søren Lophaven, Josh Noone, Michael Lyng Wolden

Diabetes Obes Metab· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study.
Ildiko Lingvay, Andreas R Kirk, Søren Lophaven, Michael L Wolden, Jay H Shubrook

Diabetes Ther· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs).
Cyrus Desouza, Andreas R Kirk, Kamal K Mangla, Michael L Wolden, Ildiko Lingvay

BMJ Open Diabetes Res Care· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Burden of Hypoglycemia in Patients With Insulin-Treated Diabetes Mellitus in China: Analysis of Electronic Medical Records From 4 Tertiary Hospitals.
Xiaomeng Yue, Jiuhong Wu, Zhen Ruan, Michael L Wolden, Lanting Li

Value Health Reg Issues· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of switching to insulin degludec from other basal insulins in real-world clinical practice in Italy.
Steffen Haldrup, Annunziata Lapolla, Jens Gundgaard, Michael L Wolden

J Med Econ· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study.
Gian Paolo Fadini, Michael Feher, Troels Krarup Hansen, Harold W de Valk, Mette Marie Koefoed, Michael Wolden

J Clin Endocrinol Metab· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-Term Cost-Effectiveness of Switching to Insulin Degludec in Japanese Patients with Type 2 Diabetes Receiving Basal-Bolus Therapy.
Jakob Langer, Michael L Wolden, Seiya Shimoda, Miki Sato, Eiichi Araki

Diabetes Ther· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching "Real-World" Diabetes Patients to Degludec from Other Basal Insulins Provides Different Clinical Benefits According to Their Baseline Glycemic Control.
Nikolaos Tentolouris, Søren T Knudsen, Annunziata Lapolla, Michael Lyng Wolden, Steffen Haldrup

Adv Ther· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes.
Joseph Tibaldi, Martin Hadley-Brown, Andreas Liebl, Steffen Haldrup, Viktor Sandberg, Michael L Wolden

Diabetes Obes Metab· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A European, multicentre, retrospective, non-interventional study (EU-TREAT) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes.
Thorsten Siegmund, Nikolaos Tentolouris, Søren T Knudsen, Annunziata Lapolla, Rudolf Prager, Michael L Wolden

Diabetes Obes Metab· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diabetes management and daily functioning burden of non-severe hypoglycemia in Japanese people treated with insulin.
Yasuo Ohashi, Michael L Wolden, Jacob Hyllested-Winge, Meryl Brod

J Diabetes Investig· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved Glycemic Control Achieved by Switching to Insulin Degludec in Insulin-Treated Patients with Type 2 Diabetes in a Real-World Setting: a Non-interventional, Retrospective Cohort Study.
Cheli Melzer Cohen, Brian Larsen Thorsted, Michael Lyng Wolden, Gabriel Chodick, Avraham Karasik

Diabetes Ther· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insulin Degludec in Clinical Practice: A Review of Japanese Real-World Data.
Kohei Kaku, Michael Lyng Wolden, Jacob Hyllested-Winge, Emil Nørtoft

Diabetes Ther· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Self-reported hypoglycaemia in patients with type 2 diabetes treated with insulin in the Hoorn Diabetes Care System Cohort, the Netherlands: a prospective cohort study.
Simone P Rauh, Femke Rutters, Brian L Thorsted, Michael L Wolden, Giel Nijpels

BMJ Open· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Association Between Body Mass Index and Health and Economic Outcomes in the United States.
Marco DiBonaventura, Agathe Le Lay, Maya Kumar, Mette Hammer, Michael Lyng Wolden

J Occup Environ Med· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes.
Sanjoy K Paul, Kerenaftali Klein, Brian L Thorsted, Michael L Wolden, Kamlesh Khunti

Cardiovasc Diabetol· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare resource implications of hypoglycemia-related hospital admissions and inpatient hypoglycemia: retrospective record-linked cohort studies in England.
Philip McEwan, Brian Larsen Thorsted, Michael Wolden, Judith Jacobsen, Marc Evans

BMJ Open Diabetes Res Care· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study.
Kamlesh Khunti, Melanie Davies, Azeem Majeed, Brian Larsen Thorsted, Michael Lyng Wolden

Diabetes Care· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased Risk of Severe Hypoglycemic Events with Increasing Frequency of Non-severe Hypoglycemic Events in Patients with Type 1 and Type 2 Diabetes.
Seamus Sreenan, Marc Andersen, Brian Larsen Thorsted, Michael L Wolden, Marc Evans

Diabetes Ther· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to comment on Khunti et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes care 2013;36:3411-3417.
Kamlesh Khunti, Michael L Wolden, Brian L Thorsted, Marc Andersen, Melanie J Davies

Diabetes Care· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis